Results 51 to 60 of about 13,476,144 (183)

Identification of new arylamine N-acetyltransferases and enhancing 2-acetamidophenol production in Pseudomonas chlororaphis HT66

Microbial Cell Factories, 2020
Background 2-Acetamidophenol (AAP) is an aromatic compound with the potential for antifungal, anti-inflammatory, antitumor, anti-platelet, and anti-arthritic activities.
Shuqi Guo, Yunxiao Wang, Wei Wang, Hongbo Hu, Xuehong Zhang   +4 more
doaj   +1 more source

New oxadiazole derivatives of isonicotinohydrazide in the search for antimicrobial agents: Synthesis and in vitro evaluation [PDF]

Journal of the Serbian Chemical Society, 2012
Structural modification of the front line antitubercular drug isoniazid provide a lipophilic adaptations of the drug in which hydrazide moiety of isoniazid is replaced by 1,3,4-oxadiazole heterocycles to eliminate in-vivo acetylation by arylamine N ...
Malhotra Manav, Sanduja Mohit, Samad Abdul, Deep Aakash   +3 more
doaj   +1 more source

NAT2 gene polymorphism in bladder cancer: a study from North India

International Brazilian Journal of Urology, 2004
PURPOSE: This study was conducted to examine: 1) whether the NAT2 genotypes are risk factors for bladder cancer, 2) to study possible association of tobacco usage with NAT2 genotype of these patients.
Rama D. Mittal, Daya S.L. Srivastava, Anil Mandhani   +2 more
doaj   +1 more source

Acetylator Genotype-Dependent Dyslipidemia in Rats Congenic for N-Acetyltransferase 2

Toxicology Reports, 2020
Recent reports suggest that arylamine N-acetyltransferases (NAT1 and/or NAT2) serve important roles in regulation of energy utility and insulin sensitivity. We investigated the interaction between diet (control vs. high-fat diet) and acetylator phenotype
Kyung U. Hong, Mark A. Doll, Angeliki Lykoudi, Raúl A. Salazar-González, Mariam R. Habil, Kennedy M. Walls, Alaa F. Bakr, Smita S. Ghare, Shirish S. Barve, Gavin E. Arteel, David W. Hein   +10 more
doaj   +1 more source

Acetyl coenzyme A kinetic studies on N-acetylation of environmental carcinogens by human N-acetyltransferase 1 and its NAT1*14B variant

Frontiers in Pharmacology, 2022
N-acetyltransferase 1 (NAT1) is a xenobiotic metabolizing enzyme that uses acetyl coenzyme A (AcCoA) as a cofactor for N-acetylation of many carcinogens including aromatic amines and alkylanilines. NAT1 is characterized by single nucleotide polymorphisms
Mariam R. Habil, Mark A. Doll, David W. Hein   +2 more
doaj   +1 more source

Identification and Characterization of Two Isozymic Forms of Arylamine N-Acetyltransferase in Syrian Hamster Skin [PDF]

, 1993
Arylamine N-acetyltransferase (EC 2.3.1.5) activity was examined using skin from Syrian hamster. Two isozymes of arylamine N-acetyltransferase, designated NAT-1 and NAT-2, were detected on anion-exchange high-performance liquid chromatography analysis ...
Namboodiri, M A A, Etminan, Mohammad, Pruski, Daniel, Slominski, Andrzej, Paus, Ralf, Gaudet, Stephen J   +5 more
core   +1 more source

Genomic and Sex Contributions to Interindividual Variability in Pitavastatin Bioavailability

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 1, July 2026.
ABSTRACT Aim This study investigates pharmacogenetic determinants of pitavastatin disposition using a candidate‐gene approach. Methods In 48 healthy volunteers, 138 variants across 40 genes involved in drug metabolism and transport were analysed to assess their relationship with pitavastatin pharmacokinetics, alongside the influence of sex and ...
Eva González‐Iglesias, Sofía Moreno‐Pérez de Villar, Dolores Ochoa, Manuel Román, Jesús Novalbos, Samuel Martín‐Vilchez, Alejandro de Miguel, Francisco Abad‐Santos   +7 more
wiley   +1 more source

Genetic Variant of Arylamine N-Acetyltransferase-2 G590A Polymorphism (rs1799930) in Xenobiotic Biotransformation and Tobacco-associated Periodontitis: A Cross-sectional Observational Study [PDF]

Journal of Clinical and Diagnostic Research
Introduction: Xenobiotic compounds in tobacco smoke necessitate metabolic detoxification via N-acetyltransferase enzymes; individuals harbouring the N-Acetyltransferase-2 (NAT2) (G590A) polymorphism exhibit impaired biotransformation proficiency, thereby
Dhathri Priya Bandi, Dhayanand John Victor, Sangeetha Subramanian, Balasubramanian Krishnaswamy   +3 more
doaj   +1 more source

PharmVar GeneFocus: NAT2—Genetic Variation and Updated Nomenclature

Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 859-871, April 2026.
The Pharmacogene Variation Consortium (PharmVar) provides nomenclature for the highly polymorphic human N‐acetyltransferase 2 (NAT2) gene. NAT2 metabolizes several clinically used drugs including isoniazid, hydralazine, amifampridine, procainamide, and sulfonamides such as dapsone, and also some highly carcinogenic arylamines.
Georgia Papanikolaou, Estella S. Poloni, José A.G. Agúndez, Raquel L.F. Teixeira, Erin C. Boone, Adalberto Rezende Santos, Michelle Whirl‐Carrillo, Katrin Sangkuhl, Teri E. Klein, Mariam R. Habil, Giannoulis Fakis, Rodney F. Minchin, David W. Hein, Sotiria Boukouvala, Andrea Gaedigk   +14 more
wiley   +1 more source

Multifaceted Small Molecules as Enzyme Modulators: Cases of Drug Discovery/Repurposing Illustrating Nature′s Pragmatism

BioMed Research International, Volume 2026, Issue 1, 2026.
The cross‐reactivity of substrates, modulators with other enzymes significantly reduces/prevents our ability to design such highly specific, that is, “one warhead–one target”, modulators. On the other hand, the potential “impasse” fuels repurposing of already developed drugs.
Monika I. Konaklieva, Balbina J. Plotkin, Nahit Gencer   +2 more
wiley   +1 more source